Ascendis Pharma A (ASND) Long-Term Investments (2018 - 2026)

Ascendis Pharma A has disclosed Long-Term Investments across 9 years of filings, most recently posting $27.6 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $27.6 million, down 35.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.6 million (down 35.95% YoY), and the FY2025 annual result was $37.9 million, up 161.0% from the prior year.
• Long-Term Investments came in at $27.6 million for Q1 2026 at Ascendis Pharma A, down from $37.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $43.1 million in Q1 2025 to a low of $6.1 million in Q4 2023.
• The 5-year median for Long-Term Investments is $26.9 million (2024), against an average of $26.4 million.
• Across the five-year window, Long-Term Investments soared 419.89% in 2022 and plunged 73.85% in 2023, its largest moves.
• Ascendis Pharma A's Long-Term Investments stood at $23.4 million in 2022, then slumped by 73.85% to $6.1 million in 2023, then jumped by 137.11% to $14.5 million in 2024, then surged by 161.0% to $37.9 million in 2025, then dropped by 27.15% to $27.6 million in 2026.
• The last three Long-Term Investments figures came in at $27.6 million (Q1 2026), $37.9 million (Q4 2025), and $33.1 million (Q3 2025), per Business Quant data.